GlassScriptPhysician profile
Ashley Galbraith
NPI 1285004382
$2,824.97
in general payments reported to CMS, 2019-2025
40 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $587 · 2023: $254 · 2024: $406 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.97 |
| Education | $110.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $449.00 | 2021-2025 | |
| Janssen Biotech, INC. | $361.24 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $216.60 | 2022-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $190.81 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $109.29 | 2023-2025 | Iclusig, Ninlaro, Vpriv |
| Eisai INC. | $96.42 | 2021-2025 | |
| Incyte Corporation | $88.20 | 2022-2025 | Monjuvi |
| Springworks Therapeutics, INC. | $86.04 | 2024-2025 | Ogsiveo |
| Astrazeneca Pharmaceuticals LP | $83.54 | 2025 | Calquence, Lynparza, Imfinzi |
| Pharmacosmos Therapeutics INC. | $76.57 | 2025 | Monoferric |
| Abbvie INC. | $75.16 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $68.50 | 2022-2025 | Lynozyfic, Libtayo |
| Exelixis INC. | $59.80 | 2022-2025 | Cabometyx |
| Amgen INC. | $56.00 | 2022 | |
| Daiichi Sankyo INC. | $55.76 | 2025 | Datroway |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $54.09 | 2025 | Brukinsa |
| Csl Behring | $52.68 | 2021 | |
| Pfizer INC. | $50.57 | 2023-2024 | |
| Genentech USA, INC. | $49.90 | 2025 | Polivy, Venclexta |
| Array Biopharma INC | $49.62 | 2025 | Braftovi, Lorbrena, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $47.17 | 2022 | |
| Lilly USA, LLC | $42.92 | 2025 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $41.79 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.97 | 2025 | |
| Sobi, INC | $32.56 | 2025 | |
| Karyopharm Therapeutics INC. | $31.61 | 2022-2025 | Xpovio |
| Puma Biotechnology, INC. | $29.78 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.59 | 2025 | Onivyde |
| Genzyme Corporation | $23.05 | 2025 | |
| Stemline Therapeutics INC. | $22.40 | 2025 | Orserdu |
| Caris Mpi, INC. | $20.65 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $18.52 | 2024 | Brukinsa |
| Novocure INC. | $18.17 | 2025 | Optune Lua (Novottf-200t) |
| Octapharma USA, INC. | $17.26 | 2023 | Panzyga |
| Epizyme, INC. | $16.47 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $15.14 | 2022 | |
| Mirati Therapeutics, INC. | $13.74 | 2024 | Krazati |
| Myovant Sciences INC. | $13.21 | 2021 | |
| Emd Serono, INC. | $12.16 | 2022 | |
| Rigel Pharmaceuticals, INC. | $12.02 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Galbraith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.